L J Schaaf
Overview
Explore the profile of L J Schaaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phelps M, Stinchcombe T, Blachly J, Zhao W, Schaaf L, Starrett S, et al.
Clin Pharmacol Ther
. 2014 May;
96(2):182-91.
PMID: 24781527
Prospective studies on epidermal growth factor receptor (EGFR) inhibitors in African Americans with non-small cell lung cancer (NSCLC) have not previously been performed. In this phase II randomized study, 55...
2.
Xu Y, Kolesar J, Schaaf L, Drengler R, Duan W, Otterson G, et al.
Cancer Chemother Pharmacol
. 2008 Sep;
63(6):1073-82.
PMID: 18795290
Purpose: Based on the preclinical evidence of topoisomerase I (Topo-1) upregulation by mitomycin C(MMC) and decreased NF-kappaB activation by celecoxib, we evaluated combinations of irinotecan/MMC and irinotecan/MMC/celecoxib in patients with...
3.
Rothenberg M, Kuhn J, Schaaf L, Rodriguez G, Eckhardt S, Villalona-Calero M, et al.
Ann Oncol
. 2002 Feb;
12(11):1631-41.
PMID: 11822765
Objectives: This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of irinotecan (CPT-11) when administered on a once-every-2-week schedule. Patients And Methods:...
4.
Pitot H, Goldberg R, Reid J, Sloan J, Skaff P, Erlichman C, et al.
Clin Cancer Res
. 2000 Jun;
6(6):2236-44.
PMID: 10873073
A Phase I study was performed to determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic profile of irinotecan (CPT-11) and its active metabolites when given on a once-every-3-week schedule....
5.
Slatter J, Schaaf L, Sams J, Feenstra K, Johnson M, Bombardt P, et al.
Drug Metab Dispos
. 2000 Mar;
28(4):423-33.
PMID: 10725311
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100 microCi) [(14)C]CPT-11 in eight patients with solid tumors. Mean +/- S.D. recovery of...
6.
DeVore R, Johnson D, Crawford J, Garst J, Dimery I, Eckardt J, et al.
J Clin Oncol
. 1999 Nov;
17(9):2710-20.
PMID: 10561345
Purpose: To evaluate the antitumor efficacy and safety of a combination of irinotecan (CPT-11) and cisplatin in patients with inoperable non-small-cell lung cancer (NSCLC). A secondary objective was to characterize...
7.
Friedman H, Petros W, Friedman A, Schaaf L, Kerby T, Lawyer J, et al.
J Clin Oncol
. 1999 May;
17(5):1516-25.
PMID: 10334539
Purpose: To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma. Patients...
8.
Drengler R, Kuhn J, Schaaf L, Rodriguez G, Villalona-Calero M, Hammond L, et al.
J Clin Oncol
. 1999 Mar;
17(2):685-96.
PMID: 10080615
Purpose: We conducted a phase I dose-escalation trial of orally administered irinotecan (CPT-11) to characterize the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetic profile, and antitumor effects in patients with...
9.
Saltz L, Spriggs D, Schaaf L, Schwartz G, Ilson D, Kemeny N, et al.
J Clin Oncol
. 1998 Dec;
16(12):3858-65.
PMID: 9850031
Purpose: In vitro synergy between cisplatin and irinotecan (CPT-11) has been reported. We designed a combination schedule of these agents to maximize the potential for synergistic interaction. Patients And Methods:...
10.
Rothenberg M, Kuhn J, Schaaf L, Drengler R, Eckhardt S, Villalona-Calero M, et al.
Oncology (Williston Park)
. 1998 Sep;
12(8 Suppl 6):68-71.
PMID: 9726095
Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of...